H.R. 1672 · 119th Congress
Maintaining Investments in New Innovation Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Not yet voted on. This bill is still a proposal: it hasn't reached a floor vote, and its text can change in committee or on the floor before any vote.
D
DavisSponsor51 cosponsors · 7 D, 44 R
R
Allen
AB
R
Bean
DC
R
Crenshaw
JG
D
Gottheimer
RH
R
Hudson
JJ
R
Joyce
JM
D
Morelle
BM
R
Moore
MM
R
Miller-Meeks
SP
D
Peters
CT
R
Tenney
BV
R
Van Duyne
RY
R
Yakym
ND
R
Dunn
KH
R
Hern
MC
R
Carey
JS
R
Shreve
AP
R
Pfluger
PS
R
Sessions
AM
R
McDowell
MK
R
Kelly
CF
R
Fleischmann
NM
R
Malliotakis
DM
R
Meuser
BP
D
Pettersen
TB
R
Balderson
TM
R
Moore
KC
R
Calvert
CC
R
(Chuck) Edwards
JM
R
Moolenaar
RW
R
Weber
VF
R
Fong
BJ
R
Jack
NM
R
Moran
MH
R
Haridopolos
TK
R
Kean
LL
R
Lee
AH
R
Hinson
KM
D
Mullin
ML
R
Lawler
AB
R
Barr
GB
R
Bilirakis
NL
R
Langworthy
AS
R
Smith
LS
R
Smucker
GE
R
Evans
BC
R
Carter
JM
D
Moskowitz
BF
R
Fitzpatrick
VG
D
Gonzalez
MR
R
Rulli13 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026.
What it does: CRS summary · Introduced in House · Feb 27, 2025
Maintaining Investments in New Innovation Act
This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Maintaining Investments in New Innovation Act
Latest action (Feb 27, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Policy area: Health · Origin: House · Introduced: Feb 27, 2025
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.